Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays ...

Source: Pediatric Rheumatology - December 14, 2018 Category: Rheumatology Authors: Ju-Yang Jung, Moon-Young Kim, Chang-Hee Suh and Hyoun-Ah Kim Tags: Review Source Type: research